MAPT and Alzheimer disease: This is coupled with the finding of plasma P-tau217 levels increasing during the early preclinical stages of Alzheimer’s disease when insoluble tau aggregates are not yet detectable by tau-positron emission tomography (PET), presenting an early biomarker (38, 39).